CD63 and non-small cell lung carcinoma: A previous TEP study in non-small cell lung cancer showed stable levels of platelet activation markers such as P-selectin and CD63 for different processing times, but the sample size was small (n = 6) and the same study did show enhanced platelet activation related gene expression in controls vs cases, which was not discussed in depth [11].